论文部分内容阅读
目的观察替吉奥单药化疗对老年晚期胰腺癌的疗效、不良反应及生活质量评分改善情况。方法 29例IV期胰腺癌,单药替吉奥胶囊口服化疗,服用4周,休息2周;均使用至肿瘤进展或不能耐受毒性。每2个周期后影像学检查并按实体瘤疗效评价标准(RECIST)评价疗效、观察化疗毒性并评估生活体能评分。结果 CR 0例,PR 11例,SD 5例,PD 13例,总有效率37.9%(11/29),疾病控制率为55.2%(16/29);胃肠道毒性、神经毒性、骨髓抑制分别为24.1%(7/29)、13.8%(4/29)、79.3%(23/29);仅见轻度肝、肾毒性,未发现3~4级毒性及手足综合征;体能评分及生活治疗评估获得6例改善、9例稳定和14例下降,生存质量改善率为51.7%(15/29)。结论单药替吉奥可以作为老年晚期胰腺癌姑息化疗的方案之一。
Objective To observe the efficacy, adverse reaction and quality of life improvement of the efficacy and safety of tizoglu monotherapy in elderly patients with advanced pancreatic cancer. Methods Twenty-nine patients with stage IV pancreatic cancer were treated with oral single dose of Teglitazone for 4 weeks and rest for 2 weeks. All patients were treated with tumor progression or could not tolerate toxicity. Imaging was performed every 2 cycles and evaluated for efficacy against RECIST. Chemotherapy toxicity was assessed and life fitness scores were assessed. Results CR 0, PR 11, SD 5, and PD 13 cases showed a total effective rate of 37.9% (11/29) and a disease control rate of 55.2% (16/29). Gastrointestinal toxicity, neurotoxicity, myelosuppression (7/29), 13.8% (4/29) and 79.3% (23/29) respectively. Only mild liver and kidney toxicity were found. Grade 3 to 4 toxicities and hand-foot syndrome were not found. Physical fitness score and life expectancy Treatment evaluation was improved in 6 cases, 9 cases were stable and 14 cases were decreased. The quality of life improvement rate was 51.7% (15/29). Conclusion Single-agent treatment of Gio can be used as one of the options for palliative chemotherapy in elderly patients with advanced pancreatic cancer.